[{"id":"343f189d-c6cb-4a8b-b082-0b802260f284","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320809","created_at":"2022-04-11T13:52:57.991Z","updated_at":"2024-07-02T16:35:31.834Z","phase":"Phase 1","brief_title":"Study of 3D189 in Patients With Hematologic Malignancies","source_id_and_acronym":"NCT05320809","lead_sponsor":"3D Medicines","biomarkers":" WT1","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zeltherva (galinpepimut-S)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-10-25"},{"id":"7906adea-ffc6-4844-a4f9-9ece80ef4a3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05360680","created_at":"2022-05-05T00:56:28.559Z","updated_at":"2024-07-02T16:35:35.573Z","phase":"Phase 1","brief_title":"A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers","source_id_and_acronym":"NCT05360680","lead_sponsor":"Cue Biopharma","biomarkers":" WT1 • CTLA4","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["WT1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CUE-102"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2023-09-27"},{"id":"03185639-6494-4888-9d7d-ca64f80d0912","acronym":"BEACON","url":"https://clinicaltrials.gov/study/NCT03363867","created_at":"2021-01-18T16:36:09.574Z","updated_at":"2024-07-02T16:35:40.759Z","phase":"Phase 2","brief_title":"BEACON - ABC in Recurrent Platinum Resistant HGSOC","source_id_and_acronym":"NCT03363867 - BEACON","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" WT1 • MUC16 • PAX8","pipe":" | ","alterations":" WT1 positive","tags":["WT1 • MUC16 • PAX8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Cotellic (cobimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-08-07"},{"id":"6cd6fea1-b47e-41c8-8a34-ff357b707a61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02737787","created_at":"2021-01-18T13:24:34.815Z","updated_at":"2024-07-02T16:35:51.110Z","phase":"Phase 1","brief_title":"A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer","source_id_and_acronym":"NCT02737787","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1 • MUC16 • CTAG1B","pipe":" | ","alterations":" WT1 expression • CTAG1B expression • WT1 positive","tags":["WT1 • MUC16 • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • CTAG1B expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 04/06/2023","primary_completion_date":" 04/06/2023","study_txt":" Completion: 04/06/2023","study_completion_date":" 04/06/2023","last_update_posted":"2023-04-07"},{"id":"baa7e829-6923-4d37-b1b8-aed8bbc1d4c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01827137","created_at":"2021-01-29T07:04:33.744Z","updated_at":"2024-07-02T16:36:51.495Z","phase":"","brief_title":"WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation","source_id_and_acronym":"NCT01827137","lead_sponsor":"Sellas Life Sciences Group","biomarkers":" IFNG • WT1 • CD4","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["IFNG • WT1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Unknown status","enrollment":" Enrollment 22","initiation":"Initiation: 04/01/2013","start_date":" 04/01/2013","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 08/01/2020","study_completion_date":" 08/01/2020","last_update_posted":"2020-01-10"},{"id":"f89e6d15-3096-418f-a740-bebeaa6005f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT00179790","created_at":"2021-01-18T00:36:33.837Z","updated_at":"2024-07-02T16:37:24.720Z","phase":"Phase 1/2","brief_title":"Reduced Intensity Transplant Using Extracorporeal Photopheresis","source_id_and_acronym":"NCT00179790","lead_sponsor":"Ann \u0026 Robert H Lurie Children's Hospital of Chicago","biomarkers":" IFNG • TNFA • WT1 • IL2RA • CD4 • IL10 • IL4 • ISG20","pipe":" | ","alterations":" WT1 expression • WT1 positive","tags":["IFNG • TNFA • WT1 • IL2RA • CD4 • IL10 • IL4 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WT1 expression • WT1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 07/01/2005","start_date":" 07/01/2005","primary_txt":" Primary completion: 06/01/2010","primary_completion_date":" 06/01/2010","study_txt":" Completion: 01/01/2015","study_completion_date":" 01/01/2015","last_update_posted":"2017-03-06"}]